Logo image of ALNEV.PA

NEOVACS (ALNEV.PA) Stock Fundamental Analysis

EPA:ALNEV - Euronext Paris - Matif - FR001400TG47 - Common Stock - Currency: EUR

0.003  0 (0%)

Fundamental Rating

1

Taking everything into account, ALNEV scores 1 out of 10 in our fundamental rating. ALNEV was compared to 71 industry peers in the Biotechnology industry. ALNEV has a bad profitability rating. Also its financial health evaluation is rather negative. ALNEV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALNEV has reported negative net income.
In the past year ALNEV has reported a negative cash flow from operations.
ALNEV had negative earnings in each of the past 5 years.
ALNEV had a negative operating cash flow in each of the past 5 years.
ALNEV.PA Yearly Net Income VS EBIT VS OCF VS FCFALNEV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -149.13%, ALNEV is not doing good in the industry: 78.87% of the companies in the same industry are doing better.
With a Return On Equity value of -182.23%, ALNEV perfoms like the industry average, outperforming 40.85% of the companies in the same industry.
Industry RankSector Rank
ROA -149.13%
ROE -182.23%
ROIC N/A
ROA(3y)-57.39%
ROA(5y)-48.39%
ROE(3y)-69.07%
ROE(5y)-57.98%
ROIC(3y)N/A
ROIC(5y)N/A
ALNEV.PA Yearly ROA, ROE, ROICALNEV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

ALNEV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALNEV.PA Yearly Profit, Operating, Gross MarginsALNEV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

2

2. Health

2.1 Basic Checks

ALNEV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALNEV has been increased compared to 1 year ago.
ALNEV has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALNEV has an improved debt to assets ratio.
ALNEV.PA Yearly Shares OutstandingALNEV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K
ALNEV.PA Yearly Total Debt VS Total AssetsALNEV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -4.88, we must say that ALNEV is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.88, ALNEV is not doing good in the industry: 69.01% of the companies in the same industry are doing better.
ALNEV has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ALNEV's Debt to Equity ratio of 0.01 is amongst the best of the industry. ALNEV outperforms 80.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -4.88
ROIC/WACCN/A
WACC3.83%
ALNEV.PA Yearly LT Debt VS Equity VS FCFALNEV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 0.64 indicates that ALNEV may have some problems paying its short term obligations.
ALNEV has a Current ratio of 0.64. This is in the lower half of the industry: ALNEV underperforms 78.87% of its industry peers.
ALNEV has a Quick Ratio of 0.64. This is a bad value and indicates that ALNEV is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.64, ALNEV is doing worse than 76.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.64
Quick Ratio 0.64
ALNEV.PA Yearly Current Assets VS Current LiabilitesALNEV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

3

3. Growth

3.1 Past

ALNEV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.66%, which is quite impressive.
ALNEV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -45.39%.
Measured over the past years, ALNEV shows a very strong growth in Revenue. The Revenue has been growing by 134.81% on average per year.
EPS 1Y (TTM)64.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.98%
Revenue 1Y (TTM)-45.39%
Revenue growth 3Y134.81%
Revenue growth 5YN/A
Sales Q2Q%-90.49%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALNEV.PA Yearly Revenue VS EstimatesALNEV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 200K 400K 600K 800K
ALNEV.PA Yearly EPS VS EstimatesALNEV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 -50B -100B -150B -200B -250B

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALNEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALNEV.PA Price Earnings VS Forward Price EarningsALNEV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.34
ALNEV.PA Per share dataALNEV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10K -20K -30K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALNEV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEOVACS

EPA:ALNEV (6/3/2025, 7:00:00 PM)

0.003

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap6.21K
Analysts86.67
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B 0
P/tB 0
EV/EBITDA -1.34
EPS(TTM)-33334.67
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.78
FCFYN/A
OCF(TTM)-1.74
OCFYN/A
SpS0.14
BVpS8.73
TBVpS8.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -149.13%
ROE -182.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.39%
ROA(5y)-48.39%
ROE(3y)-69.07%
ROE(5y)-57.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 0.72
Cap/Depr 1.15%
Cap/Sales 27.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.64
Quick Ratio 0.64
Altman-Z -4.88
F-Score3
WACC3.83%
ROIC/WACCN/A
Cap/Depr(3y)12.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)4797.67%
Cap/Sales(5y)3330.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.98%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-45.39%
Revenue growth 3Y134.81%
Revenue growth 5YN/A
Sales Q2Q%-90.49%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-73.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-88.23%
OCF growth 3YN/A
OCF growth 5YN/A